AMRX, US03168L1052

Amneal Pharmaceuticals stock: EU authorizes Adcomfo biosimilar

Published on 11/20/2026 at 22:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amneal Pharmaceuticals stock has a new regulatory milestone as Europe authorizes its Adcomfo biosimilar to XOLAIR. The U.S. application remains under FDA review.

European expansion for biosimilar portfolio

  • The European Commission authorized Adcomfo for several allergic conditions, including severe persistent allergic asthma and chronic spontaneous urticaria.
  • Amneal acquired Adcomfo developer Kashiv BioSciences in August 2026 after earlier UK authorization and a positive European Medicines Agency committee opinion.
  • ADVANZ PHARMA holds European marketing authorization and regional commercialization rights through its partnership with Alvotech.
AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals said on Tuesday, November 17, that the European Commission granted marketing authorization for Adcomfo, its omalizumab biosimilar to XOLAIR. The approval was announced in a Amneal Pharmaceuticals press release.

European authorization expands reach

Adcomfo is approved as an add-on treatment for severe persistent allergic asthma in eligible patients aged six and older. The authorization also covers adults with severe chronic rhinosinusitis with nasal polyps and adults and adolescents aged 12 and older with chronic spontaneous urticaria who have not responded adequately to H1 antihistamines.

The product was developed by Kashiv BioSciences with Alvotech, and Amneal acquired Kashiv in August 2026. The European decision followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in September and UK authorization in March.

Commercial rights and U.S. review

Adcomfo is available in 75 milligram, 150 milligram and 300 milligram pre-filled syringe presentations, as well as 75 milligram and 150 milligram pre-filled pen configurations. ADVANZ PHARMA holds the European marketing authorization and regional commercialization rights through its partnership with Alvotech.

Amneal's confirmatory study enrolled 600 patients with chronic spontaneous urticaria and met its primary efficacy endpoint, showing equivalent efficacy to XOLAIR based on the change in weekly Itch Severity Score at Week 12, with comparable safety. The company's U.S. Biologics License Application for the proposed XOLAIR biosimilar remains under review by the Food and Drug Administration.

Amneal Pharmaceuticals stock traded at 19.30 euros on Lang & Schwarz at 22:22 CET on Friday, November 20, 2026.

Amneal Pharmaceuticals

  • Company: Amneal Pharmaceuticals, Inc.
  • ISIN: US03168L1052
  • Ticker: AMRX
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 19.30 euros on November 20, 2026, at 22:22 CET

The S&P 500 sets the relevant U.S. market backdrop for Amneal Pharmaceuticals.

More news and analyses on Amneal Pharmaceuticals stock

Disclaimer...
en | US03168L1052 | AMRX | boerse | 70541152 | bgmi